FDA reportedly expected to approve boosters for 12 to 15 year-olds

Nation and World News

Jack Reed, 13, receives his first dose of the Pfizer-BioNTech vaccine by Dr. David Wahl, who is retired but came to help with the vaccination clinic, Thursday, May 13, 2021 at Vail Health Hospital in Vail, Colo. (Chris Dillmann/Vail Daily via AP)

CHICAGO (NewsNation Now) — The U.S. Food and Drug Administration is expected to authorize booster doses of Pfizer-BioNTech’s coronavirus vaccine for 12 to 15-year-olds on Monday, the New York Times reported, citing people familiar with the agency’s deliberations.

The Times also reports U.S. regulators plan to allow both adolescents and adults to get an extra shot of Pfizer’s vaccine five months after receiving a second vaccine dose instead of the current six-month window.

A booster shot is also set to be authorized for children ages 5 to 11 with immune deficiencies.

NewsNation reached out to the FDA for comment Thursday. The agency replied, “unfortunately we don’t have any information to share.”

Two months after vaccinations were approved for children ages 5 to 11, about 14% are fully protected, CDC data shows. The rate is higher for 12 to 17-year-olds, at nearly 53%.

The Centers for Disease Control and Prevention’s vaccine advisory committee is planning to meet next week to vote on whether to recommend the changes. If the committee agrees with the FDA authorizations, Dr. Rochelle P. Walensky, the CDC director, will endorse the recommendations.

The push for boosters comes as the highly transmissible omicron variant continues to spread and COVID-19 hospitalizations among children are on the rise.

“Virtually all, not 100% but close to that, of the children who are seriously ill in a hospital from COVID-19 are children whose parents decided they did not want to vaccinate them. That is avoidable,” Dr. Anthony Fauci told NewsNation.

Facui says the country’s best defense for children is proven to be vaccination. He urged parents to “think about the individual safety of the children.”

Copyright 2022 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

DOWNLOAD THE APP!

Join our daily newsletter!

Click for latest news and information

TRENDING HEADLINES